Oct. 08, 2024
Jian Zuo, CEO of Ting Therapeutics, discusses the latest updates on otoprotective agents for three conditions: antibiotic-induced hearing loss, cisplatin-induced hearing loss, and noise-induced hearing loss. Dr. Zuo explains the science behind the company’s innovative drug candidates and how they aim to address the unmet need for hearing protection. He provides an overview of Ting Therapeutics’ preclinical research, outlining key